<DOC>
	<DOCNO>NCT01563185</DOCNO>
	<brief_summary>The primary objective Phase 4 , multi-center , open-label study evaluate safety tolerability DUEXIS Juvenile Idiopathic Arthritis ( JIA ) patient age 10 year 16 year , 11 month , treat 24 week . The secondary objective evaluate PK characteristic DUEXIS JIA patient evaluate sign symptom JIA patient age 10 year 16 year , 11 month receive DUEXIS 24 week .</brief_summary>
	<brief_title>Open-label Safety Pharmacokinetic Study DUEXISÂ® ( Ibuprofen Famotidine ) Tablets Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>Approximately 30 JIA patient meet eligibility criterion expect require daily administration NSAID 24 week enrol . A subset approximately 6 patient participate single dose PK study Day 0 abbreviate PK profile perform Week 4 possible . Multiple dose PK sample occur enrol patient .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1 . Patient guardian willing consent undergo 24 week treatment DUEXIS ( ibuprofen 800 mg/famotidine 26.6 mg ) oral tablet three time daily . 2 . Patient male female , age 10 year 16 year , 11 month . 3 . Patient diagnose JIA &gt; 1 month include oligoarthritis , polyarthritis rheumatoid factor ( RF ) + , polyarthritis RF , psoriatic arthritis , enthesitisrelated arthritis , undifferentiated systemic arthritis without systemic feature past 6 month . 4 . Patient must currently active articular disease define &gt; 1 active joint ( i.e. , presence swelling , swell present , limitation motion [ LOM ] accompany pain , tenderness , ) . 5 . Based upon investigator judgment , give current treatment patient receive level disease activity , determine appropriate patient undergo 24 week treatment DUEXIS ( ibuprofen 800 mg/famotidine 26.6 mg ) oral tablet three time daily . The investigator use his/her clinical judgment determine duration treatment patient base standard care 24 week treatment . 6 . Weight &gt; 48 kg body mass index ( BMI ) &gt; 5th percentile use Centers Disease Control ( CDC ) BMI percentile calculator child teen screen visit . 7 . Patient able swallow DUEXIS tablet whole . 8 . For single dose pharmacokinetic ( PK ) subset , patient guardian must willing participate serial blood sample collection Day 0 Week 4 . 9 . Female patient childbearing potential male patient must agree use medically acceptable method contraception , include abstinence , throughout entire study period . 10 . Patient willing able comply prescribe treatment protocol evaluation . 1 . Patient history experience follow : NSAIDassociated and/or primary peptic ulcer diseaseassociated serious gastrointestinal complication perforation ulcer , gastric outlet obstruction due ulcer , and/or acute gastrointestinal bleeding NSAIDinduced asthma exacerbation , acute renal failure , interstitial nephritis , and/or hepatitis Malignant disease gastrointestinal tract Erosive esophagitis Coronary artery bypass graft ( CABG ) surgery within 14 day prior study Day 0 Uncontrolled diabetes mellitus evidence Hemoglobin A1c &gt; 7 % Known history human immunodeficiency virus ( HIV ) , hepatitis B , and/or hepatitis C. 2 . Current symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological , cerebral disease . 3 . JIA disease severe define either physician 's parent 's global assessment &gt; 90 100 point scale . 4 . Systemic JIA follow manifestation within last 6 month prior enrollment : intermittent fever due JIA , rheumatoid rash , hepatosplenomegaly , pleuritis , pericarditis , macrophage activation syndrome . 5 . Active uveitis . 6 . Presence rheumatic disease major chronic infectious , inflammatory , immunologic disease ( e.g. , inflammatory bowel disease , hypogammaglobulinemia , systemic lupus erythematosus , etc. ) . 7 . Presence screen history disease JIA require use chronic systemic corticosteroid . 8 . History clinically significant drug alcohol abuse . 9 . Presence screen follow laboratory value : Hemoglobin &lt; 9.0 g/dL White blood cell &lt; 2000/mm^3 ( 2 x 109/L ) Platelets &lt; 150,000/mm^3 ( 150 x 109/L ) Serum creatinine &gt; 1.5 time upper limit normal Serum ALT AST &gt; 2.0 time upper limit normal H. pylorus positive Any lab value opinion investigator might place patient unacceptable risk participation study . 10 . Methotrexate &gt; 20 mg/M^2/week &gt; 40 mg/week . 11 . Patient currently participate investigational drug study , patient participate investigational drug study within 30 day ( &lt; 5 terminal halflives elimination ) prior study entry . 12 . Females pregnant breast feeding . 13 . Female patient positive serum pregnancy test Screening and/or positive urine pregnancy test Study Day 0 . 14 . Patient concomitant disease condition , opinion Investigator , could interfere conduct study could put patient unacceptable risk</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>JIA</keyword>
	<keyword>ibuprofen</keyword>
	<keyword>famotidine</keyword>
	<keyword>pediatrics</keyword>
	<keyword>&gt; 1 month</keyword>
</DOC>